DCM
EBS icon

Dupont Capital Management’s Emergent Biosolutions EBS Stock Holding History

Dupont Capital Management’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-10,208
Closed -$214K – 1456
2022
Q3 		$214K Sell
10,208
-3,999
-28% -$111K 0.01% 856
2022
Q2 		$441K Buy
14,207
+8,080
+132% +$276K 0.02% 763
2022
Q1 		$252K Sell
6,127
-542
-8% -$23.9K 0.01% 974
2021
Q4 		$290K Sell
6,669
-4,689
-41% -$212K 0.01% 984
2021
Q3 		$569K Sell
11,358
-2,597
-19% -$157K 0.02% 804
2021
Q2 		$879K Hold
13,955
– – 0.02% 690
2021
Q1 		$1.3M Sell
13,955
-1,307
-9% -$134K 0.03% 495
2020
Q4 		$1.37M Buy
15,262
+5,834
+62% +$535K 0.03% 447
2020
Q3 		$974K Buy
9,428
+2,157
+30% +$233K 0.02% 525
2020
Q2 		$575K Sell
7,271
-4,484
-38% -$334K 0.01% 708
2020
Q1 		$680K Sell
11,755
-16,231
-58% -$935K 0.02% 569
2019
Q4 		$1.51M Hold
27,986
– – 0.03% 430
2019
Q3 		$1.46M Buy
27,986
+18,475
+194% +$861K 0.03% 421
2019
Q2 		$459K Sell
9,511
-4,431
-32% -$212K 0.01% 825
2019
Q1 		$704K Sell
13,942
-705
-5% -$41.6K 0.02% 640
2018
Q4 		$868K Sell
14,647
-19,092
-57% -$1.23M 0.02% 572
2018
Q3 		$2.22M Buy
33,739
+19,486
+137% +$1.14M 0.05% 354
2018
Q2 		$720K Hold
14,253
– – 0.02% 630
2018
Q1 		$750K Sell
14,253
-11,240
-44% -$560K 0.02% 593
2017
Q4 		$1.19M Buy
+25,493
New +$1.07M 0.03% 483
2015
Q2 		– Sell
-24,661
Closed -$709K – 579
2015
Q1 		$709K Hold
24,661
– – 0.01% 484
2014
Q4 		$672K Hold
24,661
– – 0.01% 525
2014
Q3 		$526K Hold
24,661
– – 0.01% 555
2014
Q2 		$554K Hold
24,661
– – 0.01% 572
2014
Q1 		$623K Sell
24,661
-38,493
-61% -$972K 0.01% 572
2013
Q4 		$1.45M Sell
63,154
-9,782
-13% -$204K 0.03% 432
2013
Q3 		$1.39M Buy
72,936
+17,213
+31% +$307K 0.03% 440
2013
Q2 		$804K Buy
+55,723
New +$807K 0.02% 494

Other funds holding EBS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Hotchkis & Wiley Capital Management
Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Dupont Capital Management's EBS Position: Q4 2022 in Review

Dupont Capital Management sold out of Emergent Biosolutions (EBS) in Q4 2022, closing a stake of 10,208 shares — an estimated $214K sold.

Dupont Capital Management first reported a position in EBS in Q2 2013 and held it in 28 quarters. The position peaked at $2.22M in Q3 2018. 198 funds tracked by Wall St. Rank hold EBS as of Q4 2022.

  • Dupont Capital Management reported no remaining Emergent Biosolutions position as of Q4 2022 after selling out during the quarter.
  • Dupont Capital Management sold 10,208 Emergent Biosolutions shares in Q4 2022, an estimated $214K.
  • Dupont Capital Management first reported a position in Emergent Biosolutions in Q2 2013 and held it in 28 quarters.
  • Dupont Capital Management's Emergent Biosolutions position peaked at $2.22M in Q3 2018.
  • 198 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q4 2022.

Based on Dupont Capital Management's 13F filing for Q4 2022, filed 26 Jan 2023.